# OnCo record multiple-myeloma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/multiple-myeloma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "multiple-myeloma" ;
  schema:name "Multiple myeloma"@en ;
  schema:description "Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."@en ;
  schema:url <https://onco.cc/cancers/multiple-myeloma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_myeloma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q467635> ;
  schema:citation <https://en.wikipedia.org/wiki/Multiple_myeloma> ;
  onco:tag "heme", "spike" ;
  onco:related <https://onco.cc/pairings/cd38-plus-triplet/>, <https://onco.cc/pairings/bcma-then-gprc5d/>, <https://onco.cc/pairings/bispecific-infection-prophylaxis/>, <https://onco.cc/collections/mmrf/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/whole-body-mri/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/fdg-pet/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/gprc5d/>, <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/elotuzumab/>, <https://onco.cc/drugs/panobinostat/>, <https://onco.cc/drugs/sipuleucel-t/>, <https://onco.cc/drugs/fluciclovine-f18/>, <https://onco.cc/drugs/aminolevulinic-acid-gleolan/>, <https://onco.cc/drugs/pegulicianine/>, <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/palifermin/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/>, <https://onco.cc/companies/celltrion/>, <https://onco.cc/companies/chongqing-precision-biotech/>, <https://onco.cc/companies/shanghai-abelzeta/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/legend-biotech/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/gsk/>, <https://onco.cc/companies/sanofi/>, <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/genmab/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/mount-sinai/> ;
  onco:terms <https://onco.cc/terms/r-iss/>, <https://onco.cc/terms/high-risk-myeloma/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/> ;
  onco:trials <https://onco.cc/trials/nct07555938/>, <https://onco.cc/trials/nct07258511/>, <https://onco.cc/trials/nct07518186/>, <https://onco.cc/trials/nct07452198/>, <https://onco.cc/trials/nct07138209/>, <https://onco.cc/trials/quintessential-2/>, <https://onco.cc/trials/nct07297329/>, <https://onco.cc/trials/nct07579234/>, <https://onco.cc/trials/nct06508983/>, <https://onco.cc/trials/nct06868654/>, <https://onco.cc/trials/nct05730036/>, <https://onco.cc/trials/nct06952478/>, <https://onco.cc/trials/nct06464991/>, <https://onco.cc/trials/nct03844048/>, <https://onco.cc/trials/nct06956170/>, <https://onco.cc/trials/nct05438043/>, <https://onco.cc/trials/nct05572515/>, <https://onco.cc/trials/nct05623020/>, <https://onco.cc/trials/nct05827016/>, <https://onco.cc/trials/nct06152575/>, <https://onco.cc/trials/nct03539744/>, <https://onco.cc/trials/nct05519085/>, <https://onco.cc/trials/nct06514508/>, <https://onco.cc/trials/nct04975997/>, <https://onco.cc/trials/nct04162210/>, <https://onco.cc/trials/nct06413498/>, <https://onco.cc/trials/nct06158841/>, <https://onco.cc/trials/nct05020236/>, <https://onco.cc/trials/nct07095452/>, <https://onco.cc/trials/nct03246529/>, <https://onco.cc/trials/nct06208150/>, <https://onco.cc/trials/nct06679101/>, <https://onco.cc/trials/nct06868667/>, <https://onco.cc/trials/nct05552976/>, <https://onco.cc/trials/nct05317416/>, <https://onco.cc/trials/nct05552222/>, <https://onco.cc/trials/nct06045806/>, <https://onco.cc/trials/nct05455320/>, <https://onco.cc/trials/nct07393282/>, <https://onco.cc/trials/nct04270409/>, <https://onco.cc/trials/nct06980480/>, <https://onco.cc/trials/nct07742215/> ;
  onco:people <https://onco.cc/people/maria-victoria-mateos/>, <https://onco.cc/people/meletios-dimopoulos/> ;
  onco:journals <https://onco.cc/journals/blood-cancer-discovery/>, <https://onco.cc/journals/blood-cancer-journal/>, <https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/>, <https://onco.cc/journals/current-hematologic-malignancy-reports/>, <https://onco.cc/journals/haematologica/>, <https://onco.cc/journals/journal-of-hematology-and-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/cevostamab/>, <https://onco.cc/drugs/jnj-79635322/>, <https://onco.cc/drugs/purinostat/>, <https://onco.cc/drugs/gr1803/>, <https://onco.cc/drugs/qls32015/>, <https://onco.cc/drugs/arlocabtagene-autoleucel/>, <https://onco.cc/drugs/sctc21c/>, <https://onco.cc/drugs/f182112/>, <https://onco.cc/drugs/sg301/>, <https://onco.cc/drugs/gc012f/>, <https://onco.cc/drugs/azd4045/>, <https://onco.cc/drugs/sti-6129/>, <https://onco.cc/drugs/feladilimab/>, <https://onco.cc/drugs/anitocabtagene-autoleucel/>, <https://onco.cc/trials/immagine-1/>, <https://onco.cc/trials/cartitude-5/>, <https://onco.cc/drugs/iberdomide/>, <https://onco.cc/drugs/mezigdomide/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/elranatamab/>, <https://onco.cc/trials/istopmm/>, <https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/>, <https://onco.cc/ideas/idea-car-t-replaces-transplant/>, <https://onco.cc/pairings/bcma-then-gprc5d/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/drugs/belantamab-mafodotin/> ;
  onco:standardOfCare <https://onco.cc/technologies/whole-body-mri/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/trials/istopmm/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/terms/smoldering-myeloma/>, <https://onco.cc/trials/perseus/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/trials/cepheus/>, <https://onco.cc/trials/imroz/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/iberdomide/>, <https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/>, <https://onco.cc/trials/drammatic/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/trials/cartitude-4/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/trials/majestec-3/>, <https://onco.cc/drugs/idecabtagene-vicleucel/>, <https://onco.cc/trials/karmma-3/>, <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/trials/dreamm-7/>, <https://onco.cc/trials/dreamm-8/>, <https://onco.cc/drugs/carfilzomib/>, <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/elranatamab/>, <https://onco.cc/drugs/linvoseltamab/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/mezigdomide/>, <https://onco.cc/drugs/anitocabtagene-autoleucel/>, <https://onco.cc/pairings/bcma-then-gprc5d/>, <https://onco.cc/pairings/bispecific-infection-prophylaxis/>, <https://onco.cc/technologies/imrt-igrt/> .